Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Santhera Secures Exclusive Rights from NIH

Published: Monday, June 10, 2013
Last Updated: Monday, June 10, 2013
Bookmark and Share
Santhera has obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.

Santhera Pharmaceuticals has announced that it has obtained an exclusive license from the National Institutes of Health (NIH) to its rights on a patent granted in the USA for the use of idebenone for the treatment of primary progressive Multiple Sclerosis (ppMS), a currently untreatable disease affecting about 40,000 patients in the Unites States.

The NIH is investigating the efficacy of Catena® (idebenone) in ppMS in a placebo-controlled Phase II clinical trial.

Lead by the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke (NINDS), the NIH is investigating the efficacy of Catena® (idebenone) in patients with ppMS in a double-blind, placebo-controlled Phase II clinical trial (IPPoMS trial).

Santhera is providing study medication under a clinical trial agreement which gives Santhera the rights to the results. Santhera has now obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.

Patients who complete the IPPoMS trial can enter into a 12-months open-label extension trial for which Santhera and the NIH recently signed a Materials Cooperative Research and Development Agreement (M-CRADA).

"Patients with ppMS do not respond to immunomodulatory therapies with proven efficacy in relapsing remitting MS," said Bibiana Bielekova, M.D, the principal investigator of the IPPoMS trial and Chief of the Neuroimmunology Disease Unit at the NINDS.

Bielekova continued, "Accumulating data indicate that mitochondrial dysfunction and related oxidative stress may play a major role in the pathogenesis of progressive MS. Idebenone enhances mitochondrial function and acts as an anti-oxidant against membrane damage in laboratory models and is a rational treatment choice in ppMS based on these pharmacological properties. Recruitment is proceeding well in the IPPoMS trial and we are excited about the opportunity to study the potential of idebenone in this currently untreatable disease."

"We are very enthusiastic about this collaboration and about the progress currently being made. ppMS is a disease with high medical need. In contrast to other forms of MS, there is currently no treatment option available for the 10-15 % of MS patients affected by this primary progressive subtype," commented Nick Coppard, Santhera's Head of Development.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Santhera Reports Financial Results
Results for the first half year and transitions towards product company.
Tuesday, September 15, 2015
Santhera Receives European Marketing Authorization for Raxone®
First approved treatment for LHON and first approved treatment for a mitochondrial disease.
Thursday, September 10, 2015
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Tuesday, July 21, 2015
CHMP Recommends Granting a Marketing Authorization for Santhera's Raxone®
Raxone® (idebenone) for the treatment of visual impairment in adolescent and adult patients with LHON.
Friday, June 26, 2015
Santhera Update on Pre-NDA Meeting with FDA
Company plans to submit a New Drug Application for Raxone®/Catena® (idebenone) in Duchenne Muscular Dystrophy.
Tuesday, June 16, 2015
Santhera's Positive Phase III Trial in DMD Patients Published in The Lancet
First successful Phase III trial in DMD shows Raxone®/Catena® preserves respiratory function.
Thursday, April 23, 2015
Santhera Receives FDA Fast Track Designation for Raxone®/Catena®
Fast Track designation for the treatment of Duchenne Muscular Dystrophy.
Friday, April 10, 2015
Santhera Repositions Omigapil in Congenital Muscular Dystrophy
Company initiates clinical development program with public-private partners.
Thursday, July 17, 2014
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in DMD
Positive outcome indicates that Catena®/Raxone® can mitigate respiratory weakness and dysfunction.
Tuesday, May 27, 2014
Santhera Closes License-Back Deal with Takeda
Agreement with Takeda to license back previously granted European rights to Catena® in DMD.
Friday, September 27, 2013
Santhera Obtains US Patent for Use of Catena® in the Treatment of Muscular Dystrophies
The patent in the United States is supplemented by a similar patent in the European Union granted in 2010.
Wednesday, August 24, 2011
Data from Santhera's RHODOS Study to Be Presented at the European Neurological Society 2011 Meeting
Results from the RHODOS study evaluate the efficacy of Catena® in Leber Hereditary Optic Neuropathy.
Tuesday, June 07, 2011
Fipamezole Transition from Biovail Completed - Program Well Advanced Towards Phase III
Fipamezole is being developed as a potential first treatment of Dyskinesia in Parkinson's Disease.
Wednesday, February 23, 2011
Santhera Licenses Melanocortin-4 Receptor Antagonist Program to BioLineRx
BioLineRx acquires all rights to develop, sub-license and commercialize the compound.
Thursday, October 14, 2010
Santhera and Ipsen Enter into Licensing Agreement for Fipame-zole for the Treatment of Dyskinesia in Parkinson's Disease
Ipsen acquires the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of EUR 13 million.
Friday, September 03, 2010
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos